Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1026-1033, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jung, K.
Right arrow Articles by Loening, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, K.
Right arrow Articles by Loening, S. A.

Clinical Chemistry, Vol 42, 1026-1033, Copyright © 1996 by American Association for Clinical Chemistry

Analytical performance and clinical validity of two free prostate- specific antigen assays compared

K Jung, C Stephan, M Lein, W Henke, D Schnorr, B Brux, P Schurenkamper and SA Loening
Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany. jung@rz.charite.hu-berlin.de

We compared two recently introduced commercial assays (CanAg and Immulite) for measuring free prostate-specific antigen (f-PSA), total PSA (t-PSA), and the ratio of t-PSA/f-PSA (f-PSA%) in control materials and sera of 54 healthy men, 50 patients with benign prostatic hyperplasia (BPH), and 45 patients with prostate cancer (PCa). The lower detection limits for f-PSA were 0.038 microgram/L and 0.004 microgram/L for the CanAg and Immulite assays, respectively. The within- run and between-day precisions of the Immulite assay were < 5%; the CanAg assay showed a poorer precision. Whereas f-PSA values differed between controls and patients but not between BPH and PCa patients, the f-PSA% values were lower in PCa patients than in BPH patients and controls. The receiver-operating characteristic (ROC) curve showed an improved diagnostic power of f-PSA% compared with t-PSA to discriminate between BPH and PCa. Discrimination limits of 16% (CanAg assay), and 15% (Immulite assay) are recommended for f-PSA%.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
D. A. Brown, C. Stephan, R. L. Ward, M. Law, M. Hunter, A. R. Bauskin, J. Amin, K. Jung, E. P. Diamandis, G. M. Hampton, et al.
Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis
Clin. Cancer Res., January 1, 2006; 12(1): 89 - 96.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. W.S. Rutjes, J. B. Reitsma, J. P. Vandenbroucke, A. S. Glas, and P. M.M. Bossuyt
Case-Control and Two-Gate Designs in Diagnostic Accuracy Studies
Clin. Chem., August 1, 2005; 51(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Jung, J. Reiche, A. Boehme, C. Stephan, S. A. Loening, D. Schnorr, W. Hoesel, and P. Sinha
Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer
Clin. Chem., December 1, 2004; 50(12): 2292 - 2301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Stephan, H. Cammann, A. Semjonow, E. P. Diamandis, L. F.A. Wymenga, M. Lein, P. Sinha, S. A. Loening, and K. Jung
Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies
Clin. Chem., August 1, 2002; 48(8): 1279 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
J.-M. Bidart, F. Thuillier, C. Augereau, J. Chalas, A. Daver, N. Jacob, F. Labrousse, and H. Voitot
Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring
Clin. Chem., October 1, 1999; 45(10): 1695 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Gion, R. Mione, P. Barioli, M. Barichello, F. Zattoni, T. Prayer-Galetti, M. Plebani, G. Aimo, C. Terrone, F. Manferrari, et al.
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions
Clin. Chem., December 1, 1998; 44(12): 2462 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. J. Catalona, A. W. Partin, K. M. Slawin, M. K. Brawer, R. C. Flanigan, A. Patel, J. P. Richie, J. B. deKernion, P. C. Walsh, P. T. Scardino, et al.
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
JAMA, May 20, 1998; 279(19): 1542 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. L. Woodrum, C. M. French, T. M. Hill, S. J. Roman, H. L. Slatore, J. L. Shaffer, L. G. York, K. L. Eure, K. G. Loveland, G. H. Gasior, et al.
Analytical performance of the Tandem(R)-R free PSA immunoassay measuring free prostate-specific antigen
Clin. Chem., July 1, 1997; 43(7): 1203 - 1208.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.